Lapatinib (GW572016)

A quinazoline derivative that inhibits EPIDERMAL GROWTH FACTOR RECEPTOR and HER2 (RECEPTOR, ERBB-2) tyrosine kinases. It is used for the treatment of advanced or metastatic breast cancer, where tumors overexpress HER2.

Also Known As:

Networked: 1823 relevant articles (275 outcomes, 604 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	de Azambuja, Evandro: 31 articles (10/2021 - 03/2008)
2.	Baselga, José: 25 articles (01/2019 - 04/2007)
3.	Koch, Kevin M: 24 articles (12/2017 - 01/2005)
4.	Kim, Sung-Bae: 21 articles (11/2021 - 11/2010)
5.	Crown, John: 21 articles (01/2021 - 12/2006)
6.	Spector, Neil L: 18 articles (01/2015 - 09/2002)
7.	Schiff, Rachel: 17 articles (05/2021 - 01/2011)
8.	Press, Michael F: 17 articles (01/2021 - 12/2008)
9.	Untch, Michael: 17 articles (01/2021 - 02/2006)
10.	Hilsenbeck, Susan G: 16 articles (05/2021 - 05/2008)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 05/30/2017 - "These results suggest that ERRF plays an important role in lapatinib response of ERBB2-positive breast cancer, and further study of ERRF could lead to improved prediction and sensitivity of lapatinib response." 11/01/2016 - "Lapatinib was demonstrated to be beneficial in patients with HER2-positive locally advanced and metastatic breast cancer. " 05/23/2021 - "Given that nelatinib has a superior efficacy than lapatinib, it is expected to provide more ideas and options for the treatment strategies of breast cancer. " 10/01/2020 - "Finally, we demonstrate that, in HER2-positive breast tumors, inhibition of EphB4 combined with Lapatinib is more effective than either alone. " 04/03/2012 - "Preclinical and clinical trials of lapatinib have shown that it is effective in the treatment on HER2+ breast cancer. "
2.	Neoplasms (Cancer) 08/01/2011 - "Treatment with lapatinib beginning 5 days after MNU was highly effective in preventing cancer development. " 08/15/2019 - "This lead compound (23) was assessed for its efficacy in an EGFR positive xenograft model, where it successfully inhibited tumor growth, with a similar efficacy with that of lapatinib and with minimal phenotypic toxicity." 01/01/2015 - "The above results indicate that lapatinib is effective in decreasing HER2-positive CTCs in patients with MBC irrespectively of the HER2 status of the primary tumor and imply the feasibility of monitoring the molecular changes on CTCs during treatment with targeted agents. " 01/01/2017 - "Furthermore, we demonstrated that short-term lapatinib exposure resulted in life-long protective effects, as supported by increased tumor latency in lapatinib-treated mice compared to the control mice. " 03/01/2014 - "The efficacy of treatments involving lapatinib for patients with metastatic breast cancers was evaluated in a Bayesian metaanalysis of published data from randomized controlled clinical trials. "
3.	Neoplasm Metastasis (Metastasis) 11/01/2012 - "Lapatinib alone was effective against the multiple liver metastases. " 01/01/2019 - "Any use of lapatinib after development of brain metastasis improved median survival compared to SRS without lapatinib (27.3 vs 19.5 months, p = 0.03). " 11/15/2010 - "Lapatinib has shown early promise in treatment of central nervous system metastasis and is being further evaluated in various clinical settings. " 06/01/2019 - "This study demonstrated that HER2 inhibition is a promising therapeutic strategy for GBC with HER2 amplification and, combined with lapatinib, it can effectively target brain metastasis." 01/01/2017 - "The aim of this 'field-practice' study was to investigate the efficacy and safety of T-DM1, focusing on treatment line, previous lapatinib treatment and patterns of metastasis. "
4.	Brain Neoplasms (Brain Tumor) 01/01/2019 - "The addition of concurrent lapatinib to SRS was associated with improved complete response rates among patients with HER2-positive brain metastases." 12/01/2011 - "Lapatinib was restarted, resulting in an immediate improvement in the symptoms and a reduction in the skin and brain metastases. " 01/01/2019 - "The objective of this study was to investigate the impact of lapatinib combined with stereotactic radiosurgery (SRS) on local control of brain metastases. " 01/01/2015 - "Increased lapatinib uptake was observed in brain metastases but not in normal brain. " 08/01/2013 - "The efficacy, safety, and pharmacokinetics of lapatinib 750 mg given twice daily to Japanese HER2-overexpressing MBC patients with brain metastases were assessed as part of the international clinical study. "
5.	Stomach Neoplasms (Stomach Cancer) 08/16/2021 - "A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer." 10/01/2018 - "Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071)." 11/27/2023 - "Hence, our study has unveiled the NONHSAT160169.1/hsa-let-7c-3p/SOX2 signaling pathway as a novel and pivotal axis for comprehending and surmounting lapatinib resistance in the treatment of HER2-positive gastric cancer." 08/01/2018 - "The aim of the present study was to explore the effects of miR‑494 and FGFR2 in regulation of cancer‑initiating cell phenotypes and therapeutic efficiency of lapatinib in HER2‑positive gastric cancer. " 07/01/2018 - "Taken together, our study provides a novel mechanism for regulating lapatinib sensitivity in HER2 positive gastric cancer cells, suggesting a new strategy in clinical treatment."

Related Drugs and Biologics

1.	Trastuzumab (Herceptin)
2.	Capecitabine (Xeloda)
3.	Tyrosine Kinase Inhibitors
4.	ErbB Receptors (EGF Receptor)
5.	human ERBB2 protein
6.	Ado-Trastuzumab Emtansine
7.	Phosphotransferases (Kinase)
8.	pertuzumab
9.	Hormones (Hormone)
10.	pyrotinib

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Neoadjuvant Therapy
4.	Radiotherapy
5.	Aftercare (After-Treatment)